Bladder cancer
…, NM Hahn, JA Efstathiou, SP Lerner, PU Malmström… - The Lancet, 2016 - thelancet.com
Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount, …
treated optimally. Awareness of haematuria as the major presenting symptom is paramount, …
Guidelines on bladder cancer
W Oosterlinck, B Lobel, G Jakse, PU Malmström… - European urology, 2002 - Elsevier
Objectives: On behalf of the European Association of Urology (EAU) guidelines for diagnosis,
therapy and follow-up of bladder cancer patients were established. Criteria for …
therapy and follow-up of bladder cancer patients were established. Criteria for …
A second-look TUR in T1 transitional cell carcinoma: why?
G Jakse, F Algaba, PU Malmström, W Oosterlinck - European urology, 2004 - Elsevier
T1 transitional cell cancer of the urinary bladder is associated with a significant risk of tumor
progression when transurethral resection (TUR) is the only treatment. Additional intravesical …
progression when transurethral resection (TUR) is the only treatment. Additional intravesical …
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non …
PU Malmström, RJ Sylvester, DE Crawford, M Friedrich… - European urology, 2009 - Elsevier
… Author contributions: Per-Uno Malmström had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data analysis. …
takes responsibility for the integrity of the data and the accuracy of the data analysis. …
[PDF][PDF] Comprehensive transcriptional analysis of early-stage urothelial carcinoma
…, JB Jensen, JS Pedersen, PU Malmström… - Cancer cell, 2016 - cell.com
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely
different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage …
different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage …
[HTML][HTML] An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
…, A Hartmann, EC Zwarthoff, PU Malmström… - Nature …, 2021 - nature.com
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …
Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for photodiagnosis of superficial bladder cancer—a multicenter study
…, L Guillou, SJ Karlsen, PU Malmström… - The Journal of …, 2003 - auajournals.org
Purpose : We examined the sensitivity and specificity of Hexvix (PhotoCure ASA, Oslo, Norway)
hexyl aminolevulinate (HAL) fluorescence cystoscopy in patients with superficial bladder …
hexyl aminolevulinate (HAL) fluorescence cystoscopy in patients with superficial bladder …
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies
…, O Mestad, J Nilsson, S Nilsson, PU Malmström - European urology, 2004 - Elsevier
Objectives: A Nordic collaborative group assessed the effectiveness of cisplatinum based
combination chemotherapy prior to cystectomy in two consecutive trials. We analyzed overall …
combination chemotherapy prior to cystectomy in two consecutive trials. We analyzed overall …
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive …
…, R Wahlqvist, A Ullén, S Nilsson, PU Malmström - European urology, 2012 - Elsevier
BACKGROUND: Characterising responders to neoadjuvant chemotherapy (NAC) is important
to minimise overtreatment and the unnecessary delay of definitive treatment of urothelial …
to minimise overtreatment and the unnecessary delay of definitive treatment of urothelial …
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma
PU Malmstrom, H WIJKSTROM… - The Journal of …, 1999 - auajournals.org
Purpose : We report the 5-year followup of a randomized comparison of mitomycin C and
bacillus Calmette-Guerin (BCG) in patients with superficial bladder carcinoma. Recurrence, …
bacillus Calmette-Guerin (BCG) in patients with superficial bladder carcinoma. Recurrence, …